Philadelphia Trust Co. Takes $589,000 Position in CryoPort, Inc. $CYRX

Key Points

• Philadelphia Trust Co. invested approximately $589,000 in CryoPort, acquiring 96,836 shares of the company's stock in the first quarter.
• In the most recent quarterly earnings report, CryoPort reported a net revenue of $45.45 million, surpassing consensus estimates, but had an earnings per share loss of ($0.29).
• Recent analyst upgrades suggest a bullish outlook, with firms like Leerink Partners giving CryoPort an "outperform" rating and setting a price target of $16.00.

Philadelphia Trust Co. acquired a new stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 96,836 shares of the company's stock, valued at approximately $589,000. Philadelphia Trust Co. owned about 0.19% of CryoPort at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in CryoPort by 23.8% in the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after buying an additional 15,036 shares in the last quarter. Graham Capital Management L.P. lifted its stake in CryoPort by 24.9% in the 4th quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock valued at $221,000 after buying an additional 5,667 shares in the last quarter. Lazard Asset Management LLC purchased a new position in CryoPort in the 4th quarter valued at about $51,000. ProShare Advisors LLC purchased a new position in CryoPort in the 4th quarter valued at about $95,000. Finally, CWM LLC lifted its stake in CryoPort by 1,437.0% in the 1st quarter. CWM LLC now owns 11,328 shares of the company's stock valued at $69,000 after buying an additional 10,591 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Trading Up 0.2%

CryoPort stock traded up $0.0130 during trading on Thursday, hitting $8.6730. The company had a trading volume of 156,348 shares, compared to its average volume of 535,727. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $9.48. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. The company's 50 day simple moving average is $7.55 and its 200-day simple moving average is $6.63. The stock has a market cap of $434.26 million, a price-to-earnings ratio of 6.54 and a beta of 1.88.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort has set its FY 2025 guidance at EPS. As a group, analysts expect that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CYRX has been the topic of a number of research reports. Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th. Leerink Partners raised shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price on the stock in a research note on Wednesday, August 6th. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a research note on Wednesday, August 6th. Morgan Stanley decreased their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Finally, BTIG Research decreased their target price on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, CryoPort presently has an average rating of "Buy" and an average target price of $12.00.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 40,728 shares of the company's stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the completion of the sale, the director directly owned 92,328 shares of the company's stock, valued at approximately $668,454.72. This represents a 30.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 16,344 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total transaction of $115,388.64. Following the transaction, the chief executive officer owned 912,419 shares in the company, valued at approximately $6,441,678.14. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 490,447 shares of company stock valued at $3,337,198 in the last ninety days. 10.00% of the stock is currently owned by insiders.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.